Trifluoperazine is indicated for the treatment of generalized non-psychotic anxiety. Trihexyphenidyl is indicated for the treatment of parkinson’s disease and extrapyramidal reactions caused by drugs.
Mode of Action
Trifluoperazine blocks postsynaptic mesolimbic dopaminergic D1and D2 receptors in the brain, depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. Trihexyphenidyl is a selective M1 muscarinic acetylcholine receptor antagonist able to discriminate between the M1 (cortical or neuronal) and the peripheral muscarinic subtypes (cardiac and glandular). It partilly blocks cholinergic activity in the increase CNS, which is responsible for the symptoms of Parkinson’s disease.
Trifluoperazine Readily absorbed from the GI tract. Tmx occurs 1.5 to 6 h after oral administration. Highly bound to plasma proteins and distributed into breast milk. Hepatic metabolism, half-life: 10-20 hours Trihexyphenidyl Rapidly absorbed from the gastrointestinal tract. Half-life: 3.3-4.1 hours
Dosage and Recommendation
Trifluoperazine Adult: 2-5 mg bd gradually increased to 15-20mg daily; child: 0.02-0.05 mg/kg PO. Trihexyphenidyl Adult: initially 1mg daily, in divided doses; later 6-10mg tid.
Packing and Presentation
Available dose is trifluoperazine 5mg + trihexyphenidyl 2mg tablet.